CN119325471A - Egfr抑制剂 - Google Patents
Egfr抑制剂 Download PDFInfo
- Publication number
- CN119325471A CN119325471A CN202380044824.6A CN202380044824A CN119325471A CN 119325471 A CN119325471 A CN 119325471A CN 202380044824 A CN202380044824 A CN 202380044824A CN 119325471 A CN119325471 A CN 119325471A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- optionally substituted
- pharmaceutically acceptable
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327631P | 2022-04-05 | 2022-04-05 | |
| US63/327,631 | 2022-04-05 | ||
| PCT/US2023/017384 WO2023196283A1 (en) | 2022-04-05 | 2023-04-04 | Egfr inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119325471A true CN119325471A (zh) | 2025-01-17 |
Family
ID=86286433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380044824.6A Pending CN119325471A (zh) | 2022-04-05 | 2023-04-04 | Egfr抑制剂 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250236608A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504719A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025512957A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250012554A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119325471A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129002A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023250382A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3247645A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315980A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012267A (cg-RX-API-DMAC7.html) |
| PY (1) | PY2325218A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202404590A (cg-RX-API-DMAC7.html) |
| UY (1) | UY40220A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023196283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080784A1 (en) * | 2023-10-11 | 2025-04-17 | Blueprint Medicines Corporation | Egfr inhibitors |
| TW202530211A (zh) * | 2023-10-11 | 2025-08-01 | 美商纜圖藥品公司 | Egfr抑制劑之鹽及固體形式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012066122A1 (en) * | 2010-11-18 | 2012-05-24 | Syngenta Participations Ag | 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides |
| CN110498804A (zh) * | 2018-05-18 | 2019-11-26 | 山东轩竹医药科技有限公司 | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 |
| TW202012391A (zh) * | 2018-07-04 | 2020-04-01 | 日商第一三共股份有限公司 | 二芳基醚型喹唑啉衍生物 |
| PH12022551574A1 (en) | 2019-12-23 | 2024-02-26 | Blueprint Medicines Corp | Egfr inhibitors |
-
2023
- 2023-03-31 TW TW112112529A patent/TW202404590A/zh unknown
- 2023-04-04 WO PCT/US2023/017384 patent/WO2023196283A1/en not_active Ceased
- 2023-04-04 IL IL315980A patent/IL315980A/en unknown
- 2023-04-04 CA CA3247645A patent/CA3247645A1/en active Pending
- 2023-04-04 CN CN202380044824.6A patent/CN119325471A/zh active Pending
- 2023-04-04 EP EP23721090.1A patent/EP4504719A1/en active Pending
- 2023-04-04 PY PY202302325218A patent/PY2325218A/es unknown
- 2023-04-04 AU AU2023250382A patent/AU2023250382A1/en active Pending
- 2023-04-04 US US18/853,933 patent/US20250236608A1/en active Pending
- 2023-04-04 KR KR1020247036844A patent/KR20250012554A/ko active Pending
- 2023-04-04 JP JP2024559157A patent/JP2025512957A/ja active Pending
- 2023-04-05 AR ARP230100850A patent/AR129002A1/es unknown
- 2023-04-10 UY UY0001040220A patent/UY40220A/es unknown
-
2024
- 2024-10-03 MX MX2024012267A patent/MX2024012267A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012267A (es) | 2024-11-08 |
| UY40220A (es) | 2023-10-13 |
| PY2325218A (es) | 2023-10-17 |
| TW202404590A (zh) | 2024-02-01 |
| AR129002A1 (es) | 2024-07-03 |
| AU2023250382A1 (en) | 2024-11-14 |
| EP4504719A1 (en) | 2025-02-12 |
| KR20250012554A (ko) | 2025-01-24 |
| WO2023196283A1 (en) | 2023-10-12 |
| IL315980A (en) | 2024-11-01 |
| CA3247645A1 (en) | 2023-10-12 |
| JP2025512957A (ja) | 2025-04-22 |
| US20250236608A1 (en) | 2025-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101904632B1 (ko) | 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물 | |
| JP6524221B2 (ja) | Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| CN113061132B (zh) | 一类稠环内酰胺类化合物、制备方法和用途 | |
| CN104837829B (zh) | 抑制剂化合物 | |
| WO2023280254A1 (zh) | 一种tead抑制剂 | |
| KR20240127910A (ko) | Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물 | |
| KR20200119824A (ko) | 축합 고리 화합물 | |
| TW202019921A (zh) | 用於抑制shp2活性之雜雙環化合物 | |
| CN109422755A (zh) | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 | |
| HK1231475A1 (zh) | Tank-结合激酶抑制剂化合物 | |
| CN114945571A (zh) | 环状化合物及其使用方法 | |
| WO2016116900A1 (en) | Inhibitors of trka kinase | |
| CN104903320A (zh) | 含氮杂环化合物或其盐 | |
| CN104703988B (zh) | 新的三唑并吡嗪衍生物及其用途 | |
| CN114466850A (zh) | [1,2,4]三唑并[1,5-c]喹唑啉-5-胺 | |
| CN117940424A (zh) | Egfr抑制剂 | |
| WO2022165530A1 (en) | Small molecule inhibitors of salt inducible kinases | |
| CN112047939A (zh) | 一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物 | |
| CN117858872A (zh) | 用于治疗癌症的杂环egfr抑制剂 | |
| AU2023250382A1 (en) | Egfr inhibitors | |
| TWI869674B (zh) | 雜芳基衍生化合物及其用途 | |
| TW202300152A (zh) | Egfr抑制劑 | |
| WO2025080784A1 (en) | Egfr inhibitors | |
| CN117916232A (zh) | 用于治疗癌症的杂环egfr抑制剂 | |
| KR101842645B1 (ko) | 신규한 히드라진온이 치환된 피리미딘 유도체 및 그의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |